Skip to main content
. 2023 Sep 6;15(18):4436. doi: 10.3390/cancers15184436

Figure 3.

Figure 3

Kaplan–Meier estimates of the time-to-CNS-metastasis, i.e., the formation of de novo brain metastases after the start of the dabrafenib plus trametinib combination therapy. Vertical markers show censored patients. Cut-off date was 28 July 2021. Median follow-up was 13.5 months.